Don’t Miss Out: August 22, 12 PM EDT!

Register now to join the webinar.

Mark your calendar now—August 22, 2025 at 12 PM EDT—for an exclusive live webinar hosted by Creative Biolabs, spotlighting the revolutionary tumoroid-on-a-chip technology for cancer immunotherapy research.

This highly anticipated session, titled “Tumoroid-on-a-Chip as a Physiologically Relevant Model for Immunotherapy,” will be led by Dr. Mohsen Akbari, a leading innovator in microfluidics and tumor microenvironment modeling. If you're engaged in oncology, immunotherapy, or drug discovery, this is a webinar you can’t afford to miss.

�� When?

Live Broadcast: August 22, 2025 | 12:00 PM EDT (Eastern Daylight Time)

Set a reminder and reserve your seat—space is limited!

�� What to Expect:

As cancer researchers continue to face challenges in treating solid tumors like glioblastoma, tumoroid-on-a-chip platforms offer new hope. Dr. Akbari’s team has engineered a microfluidic system that replicates the tumor’s native environment—bridging the gap between 2D cell cultures and in vivo models.

Key highlights include:

Development of high-throughput tumoroid-on-plate systems

Integration of cellular heterogeneity and ECM structure

Realistic immunotherapy screening conditions

Use cases in drug development and translational oncology

This innovative platform mimics human tumor physiology more accurately than traditional methods, making it a valuable tool for testing novel therapies and improving clinical translation.

Meet the Speaker: Dr. Mohsen Akbari

Associate Professor, University of Victoria

Director, Laboratory for Innovations in Microengineering (LiME)

Renowned researcher with 140+ peer-reviewed publications (h-index 52)

Recipient of multiple international awards and fellowships

Editorial board member for Biofabrication, Micromachines, and more

With extensive experience in tissue engineering, biomaterials, and biofabrication, Dr. Akbari’s work is widely cited and has been featured by global media including BBC News, Science Daily, and CBC.